Sutterton Surgery News

26th Jan

Medication and or Long Term Condition Reviews

To all of our Sutterton Surgery Patients.
We are making some improvements to how we invite patients for medication reviews, long-term condition reviews, and any blood tests that may be required.
If you take regular medication or have a long-term condition, you may notice a change to when you are invited for these appointments.
From April, we will invite you for any required blood tests, followed by your medication review and/or long-term condition review, during the month of your birthday. You will receive your invitation in the month before your birthday to allow you time to book the necessary appointments.
During this first year of the new system, it is possible that you may receive an invitation even if you have had a recent review. If this happens, please still attend the appointment. After this initial year, your reviews will then take place once a year, aligned with your birth month.
Thank you for your cooperation as we introduce this new process.
Dawn Elkington
Practice Manager
26th Jan

Weight loss medicine – Tirzepatide (Mounjaro) Tirzepatide (also called Mounjaro®) is a weight loss medicine that makes you feel fuller for longer and therefore less hungry.

Weight loss medicine – Tirzepatide (Mounjaro)
Tirzepatide (also called Mounjaro®) is a weight loss medicine that makes you feel fuller for longer and therefore less hungry.

Access to the medication will be prioritised to ensure patients with the greatest clinical need can receive it. This approach was developed based on discussions with clinical experts and engagement with key organisations.

The following weight-related health conditions will be used to define those who are eligible first:

type 2 diabetes mellitus
high blood pressure
heart disease
obstructive sleep apnoea (when your breathing stops and starts while you sleep)
abnormal blood fats (dyslipidaemia)
Cohort 1 – will start in June 2025. At least 4 of the 5 health conditions listed above plus a BMI of at least 40 (BMI to be adjusted for ethnicity).

Cohort 2 – in addition to the patients in Group 1, access to the drug will also be offered to patients meeting the following criteria in year 2. At least 4 of the 5 health conditions listed above plus a BMI of 35 to 39.9 (BMI to be adjusted for ethnicity*).

Cohort 3 – in addition to patients in Cohorts 1 and 2, access to the drug will also be offered to patients meeting the following criteria in year 3. At least 3 of the 5 health conditions and a BMI of at least 40 (BMI to be adjusted for ethnicity).

*Due to an increased risk of heath conditions at lower BMI thresholds in the following populations, the BMI used to assess eligibility for tirzepatide (Mounjaro®) will be 2.5 kg/m2 lower for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.

If tirzepatide (Mounjaro®) is recommended, you will need to eat a balanced, reduced calorie diet and take part in physical activity regularly whilst taking the medicine.

16th Nov 2025

Bereavement Support Group

 

We wanted to spotlight our Bereavement Support Group for those who have lost loved ones. If you are interested, please give us a call and Karen Allen will be happy to discuss it further with you. Thanks!

24th May 2023

Your Repeat Prescriptions Through The NHS App

Did you know you can manage repeat prescriptions from us in the NHS App?

You can easily choose where your prescriptions are sent. So, if you know you'll be away from home or you are moving home, you can change your nominated pharmacy from within the app. 

You can also order your prescription at any time that suits you. There’s no need to wait to join a telephone queue or wait until the GP surgery opens.

It’s easy to use, and, if you hit a snag, you can go to ‘Help’ in the top right-hand corner of the app or visit this website.

Find out more about the NHS App.

Page last reviewed: 26 January 2026
Page created: 15 April 2021